Verismo to Present Interim Phase 1 Clinical Data
Elevar to Release Preclinical Analysis Results
Plans to Demonstrate Technological Differentiation

HLB Group announced that it will present the latest research results from its major anti-cancer pipeline at the 'AACR 2026 Annual Meeting,' the world's largest cancer research conference, which will be held in San Diego, United States, from April 17 to 22, 2026.


HLB Group to Present Anti-Cancer Pipeline Research Results at AACR Annual Meeting View original image

The AACR, along with the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO), is recognized as one of the world's top three cancer conferences. This global academic event brings together cancer researchers and pharmaceutical and biotechnology companies from around the world to share the latest advances in cancer research.


Verismo Therapeutics, the U.S. subsidiary of HLB Innovation, plans to present interim results from the Phase 1 clinical trial in the United States for 'SynKIR-110,' a chimeric antigen receptor T cell (CAR-T) therapy targeting solid tumors, at this AACR. Although the clinical design and progress were previously introduced at several global conferences last year, this will be the first time actual clinical data is released.


In particular, SynKIR-110 is a therapy developed based on Verismo’s proprietary 'KIR-CAR' platform technology. It is designed to overcome the issue of 'T cell exhaustion' caused by excessive T cell activation, which has been a concern with existing CAR-T therapies, raising interest in the safety and efficacy data.


HLB's subsidiary, Elevar, will also release an analysis comparing the FGFR2 selectivity of the FGFR2-targeted anti-cancer therapy 'Lirafugratinib' with existing pan-FGFR inhibitors. Lirafugratinib demonstrated its efficacy and safety as a 'best-in-class' therapy through global Phase 2 clinical data presented at the ASCO Gastrointestinal Cancers Symposium (ASCO GI 2026) in January 2026.


Lirafugratinib, which was designated as an innovative therapy in 2023, completed its U.S. Food and Drug Administration (FDA) approval application in January 2026 based on Phase 2 clinical results. The company expects that the additional analysis results to be released at this AACR will provide meaningful evidence to highlight the unique strengths of Lirafugratinib in future commercialization efforts.



An HLB Group representative stated, "With this AACR presentation, we plan to more clearly demonstrate the technological differentiation and clinical value of HLB Group's next-generation anti-cancer pipeline in the global market. Based on validated clinical and non-clinical data, we will further refine our global development strategies and accelerate clinical progress to achieve sustainable technological competitiveness in the next-generation anti-cancer drug sector."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing